Stem cell reset could open door to kidney transplants for 'Impossible' patients

NCT ID NCT07607197

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether a powerful immune reset using a patient's own stem cells can clear the antibodies that block them from receiving a kidney transplant. Ten highly sensitized adults with end-stage kidney disease will undergo intense conditioning to wipe out their immune memory, then receive their own purified stem cells to rebuild a naive immune system. The goal is to lower antibody levels enough to allow a compatible deceased-donor kidney transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Autologous hematopoietic stem cell transplantation (AHSCT) with conditioning drugs (rituximab, cyclophosphamide, thymoglobulin)
What this could lead to
If it works, this could allow highly sensitized patients to receive a compatible kidney transplant, reducing time on dialysis.
What could go wrong
This is a very early, small trial (10 people) testing an intense procedure with significant risks like infection and organ damage. The immune reset may not last or enable transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOIMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.